{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T05:54:47Z","timestamp":1778219687076,"version":"3.51.4"},"reference-count":12,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T00:00:00Z","timestamp":1685923200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["The Neurohospitalist"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:p>Background: Reversible cerebral vasoconstriction syndrome (RCVS) is a non-inflammatory vasculopathy. While most patients have good clinical outcomes, RCVS can be associated with severe brain injury from ischemic stroke, subarachnoid, and intracerebral hemorrhage. Purpose: A number of vasoactive medications have been implicated in RCVS, including triptans, amphetamines, antidepressants, and decongestants. Given the role of CGRP in modulating cerebral vasodilation, the possibility of CGRP inhibitors contributing to RCVS has been raised. Research Design: Case report at the University of Pennsylvania. Study Sample: Patient at the University of Pennsylvania. Results: We report a patient with RCVS in which severe exacerbation resulting in multifocal ischemic stroke occurred following administration of the calcitonin gene\u2013related peptide (CGRP) inhibitor fremanezumab. Conclusions: It is unclear whether fremanezumab played a role in this patient's case, but CGRP-inhibitor use should be considered as a potential precipiating factor.<\/jats:p>","DOI":"10.1177\/19418744231173832","type":"journal-article","created":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T11:53:41Z","timestamp":1685966021000},"page":"415-418","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":9,"title":["Reversible Cerebral Vasoconstriction Syndrome Exacerbation After Calcitonin Gene\u2013Related Peptide Inhibitor Administration"],"prefix":"10.1177","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8005-9111","authenticated-orcid":false,"given":"Megan","family":"Zhao","sequence":"first","affiliation":[{"name":"Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Kaiser","sequence":"additional","affiliation":[{"name":"Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA"},{"name":"Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brett","family":"Cucchiara","sequence":"additional","affiliation":[{"name":"Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA"},{"name":"Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0968-6814","authenticated-orcid":false,"given":"Jonah","family":"Zuflacht","sequence":"additional","affiliation":[{"name":"Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA"},{"name":"Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,6,5]]},"reference":[{"key":"bibr1-19418744231173832","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006367"},{"key":"bibr2-19418744231173832","doi-asserted-by":"publisher","DOI":"10.1385\/NCC:3:1:091"},{"key":"bibr3-19418744231173832","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70135-7"},{"key":"bibr4-19418744231173832","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24652"},{"key":"bibr5-19418744231173832","doi-asserted-by":"publisher","DOI":"10.1111\/head.13654"},{"key":"bibr6-19418744231173832","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.902"},{"key":"bibr7-19418744231173832","doi-asserted-by":"publisher","DOI":"10.1177\/03331024211037277"},{"key":"bibr8-19418744231173832","doi-asserted-by":"publisher","DOI":"10.1100\/tsw.2002.806"},{"key":"bibr9-19418744231173832","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25831"},{"key":"bibr10-19418744231173832","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003510"},{"key":"bibr11-19418744231173832","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2011.68"},{"key":"bibr12-19418744231173832","doi-asserted-by":"publisher","DOI":"10.1177\/0333102413485658"}],"container-title":["The Neurohospitalist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/19418744231173832","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/19418744231173832","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/19418744231173832","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:56:26Z","timestamp":1777589786000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/19418744231173832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,5]]},"references-count":12,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1177\/19418744231173832"],"URL":"https:\/\/doi.org\/10.1177\/19418744231173832","relation":{},"ISSN":["1941-8744","1941-8752"],"issn-type":[{"value":"1941-8744","type":"print"},{"value":"1941-8752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,5]]}}}